[Inflammatory bowel diseases: conservative therapy]
- PMID: 1926006
[Inflammatory bowel diseases: conservative therapy]
Abstract
Recent advances in the medical treatment of the inflammatory bowel diseases are reviewed with emphasizes on controlled clinical trials. The newly developed mesalazine contains the active moiety of sulfasalazine, the 5-aminosalicylic acid. In ulcerative colitis mesalazine appears to be as efficacious as the time-honored sulfasalazine; it has however less adverse effects. Corticosteroids remain the most effective drugs in severe attacks of all forms of inflammatory bowel diseases. The immunosuppressive agents 6-mercoptopurine and azathioprine are useful second-line drugs in otherwise refractory Crohn's disease. The place of cyclosporin is at present uncertain. Metronidazole is the only efficient antibiotics in the treatment of Crohn's disease. The relative merits of various diets are discussed.
Similar articles
-
Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease.Drug Saf. 1991 May-Jun;6(3):192-219. doi: 10.2165/00002018-199106030-00005. Drug Saf. 1991. PMID: 1676590 Review.
-
Inflammatory bowel disease: management issues during pregnancy.Arch Gynecol Obstet. 2004 Sep;270(2):79-85. doi: 10.1007/s00404-003-0489-6. Epub 2003 Apr 30. Arch Gynecol Obstet. 2004. PMID: 12721680 Review.
-
Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.Dig Liver Dis. 2005 Jun;37(6):407-17. doi: 10.1016/j.dld.2004.12.013. Dig Liver Dis. 2005. PMID: 15893279 Review.
-
Optimizing therapy for inflammatory bowel disease.Am J Gastroenterol. 1997 Dec;92(12 Suppl):12S-17S. Am J Gastroenterol. 1997. PMID: 9395347 Review.
-
Inflammatory bowel disease.CMAJ. 1989 Jul 15;141(2):113-23; discussion 123-4. CMAJ. 1989. PMID: 2568163 Free PMC article. Review.